Gene Therapy Restores Hearing to 90% of Deaf Patients

Imagine never hearing your mother's voice, music, or even an explosion next to your ear. That was life for 42 patients born with a rare form of complete deafness until a groundbreaking gene therapy changed everything.

Researchers at Mass Eye and Ear in Boston and Fudan University in China have successfully restored hearing to about 90% of patients born with autosomal recessive deafness 9, a condition caused by a missing genetic instruction. The results, published in the journal Nature, represent the largest and longest study ever conducted on gene therapy for hearing loss.

The patients ranged from babies under one year old to adults as old as 32. All were born completely deaf, unable to hear any sound whatsoever because their bodies couldn't produce otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain.

The treatment works by delivering a healthy gene directly into the ear using a modified virus. The gene carries instructions to produce the missing protein, essentially giving the body what it needs to convert sound into signals the brain can understand.

Within weeks of treatment, patients began hearing for the first time. Their hearing continued to improve over six months, with many reaching near-normal levels that have now lasted more than two years.

Some patients can even hear whispers. More importantly, children treated early enough are learning to speak, opening up entirely new ways to communicate with the world around them.

The Ripple Effect

This breakthrough is sparking a transformation across the entire field of hearing loss treatment. While this particular form of deafness affects only about 50 babies born each year in the United States, the success has energized researchers to pursue similar approaches for other genetic causes of deafness.

A treatment developed by Regeneron Pharmaceuticals could become the first gene therapy for deafness approved by the FDA in the coming months. Multiple research groups are now testing similar therapies for different forms of genetic hearing loss, which together represent a significant cause of childhood deafness.

The advances are driving new interest in screening more babies for genetic deafness early, since younger patients appear to respond best to treatment. Dr. Lawrence Lustig, who chairs the Department of Otolaryngology at Columbia University, calls the ability to restore natural hearing "a game changer for our field."

Researchers are already exploring whether gene therapy might someday treat the more common forms of hearing loss caused by aging and loud noise exposure. Multiple research groups are planning clinical trials for these more widespread conditions.

Lead researcher Zheng-Yi Chen believes this could be a one-time treatment that lasts a lifetime, profoundly transforming patients' lives from silence to sound.

The treatment appears safe so far, though patients will need continued monitoring to ensure long-term safety and lasting benefits.